Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Salubris Biotherapeutics, Inc.

Salubris Biotherapeutics Announces Positive Interim Data from the Phase 2 Trial of JK07 in Heart Failure
From Salubris Biotherapeutics, Inc.
Via Business Wire
Salubris Biotherapeutics Announces European Medicines Agency Approval to Initiate a Phase 1 Clinical Trial of JK06, a 5T4-Targeted ADC, in Solid Tumors
From Salubris Biotherapeutics, Inc.
Via Business Wire
Salubris Biotherapeutics Announces $35 Million in Financing and Provides Pipeline Progress Update
From Salubris Biotherapeutics, Inc.
Via Business Wire
Salubris Biotherapeutics Presents Positive Initial Data from Phase 1b/2 Clinical Trial of JK08 at the European Society for Medical Oncology Annual Congress 2023
From Salubris Biotherapeutics, Inc.
Via Business Wire
Salubris Biotherapeutics Presents Positive 6-Month Data from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at The Heart Failure Society of America Annual Meeting 2023
From Salubris Biotherapeutics, Inc.
Via Business Wire
Salubris Biotherapeutics Presents Positive Updates from Phase 1b Clinical Trial of JK07 in Late-Breaking Session at the European Society of Cardiology Heart Failure 2023 Congress
From Salubris Biotherapeutics, Inc.
Via Business Wire
Salubris Biotherapeutics Announces $35 Million Financing to Advance Development Activities and Provides Pipeline Updates
From Salubris Biotherapeutics, Inc.
Via Business Wire
Salubris Biotherapeutics Announces Updated Phase 1b Data Demonstrating that JK07, the First Investigational Antibody Fusion Protein for Heart Failure, Resulted in Clinically Meaningful Improvements in Ejection Fraction
From Salubris Biotherapeutics, Inc.
Via Business Wire
Salubris Biotherapeutics Announces New Pipeline Advancements and Appointment of Chief Medical Officer
From Salubris Biotherapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.